Aflibercept formulations and uses thereof
Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
1. An ophthalmic formulation, comprising:
(a) aflibercept in a concentration of 5-100 mg/mL;
(b) an acetate buffer at 5-50 mM concentration;
(c) a non-ionic surfactant;
(d) a tonicifying agent selected from the group consisting of a polyol and an amino acid, wherein the formulation has a final osmolality of about 300 mOsm/kg, and
(e) wherein the concentration of chloride anion is less than about 10 mM; and
wherein the pH of the formulation is about pH 5.0 to about pH 6.5.
2. The ophthalmic formulation of claim 1 , wherein the concentration of chloride anion is less than about 5 mM.
3. The ophthalmic formulation of claim 1 , wherein the concentration of chloride anion is less than about 1 mM.
4. The ophthalmic formulation of claim 1 , wherein the acetate buffer concentration is 5-20 mM.
5. The ophthalmic formulation of claim 1 , wherein the non-ionic surfactant is selected from the group consisting of a polysorbate, a polyethylene glycol dodecyl ether, a poloxamer, 4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, an alkylsaccharide and an alkylglycoside.
6. The ophthalmic formulation of claim 1 , wherein the non-ionic surfactant is Poloxamer 188.
7. The ophthalmic formulation of claim 1 , wherein the tonicifying agent is a polyol selected from sucrose, trehalose, sorbitol, mannitol, and glycerol.
8. The ophthalmic formulation of claim 1 , further comprising an additional amino acid stabilizing agent.
9. The ophthalmic formulation of claim 8 , wherein the additional amino acid stabilizing agent is selected from the group consisting of proline, arginine, methionine, glycine, and lysine.
10. The ophthalmic formulation of claim 1 , wherein the tonicifying agent is an amino acid selected from proline, arginine, aspartate, glutamate, glycine, histidine, isoleucine, and lysine.
11. The ophthalmic formulation of claim 1 , wherein the tonicifying agent is proline.
12. The ophthalmic formulation of claim 1 , wherein:
(a) the aflibercept concentration is 20-80 mg/mL;
(b) the acetate buffer is about 10 mM;
(c) the non-ionic surfactant is a polysorbate or a poloxamer;
(d) the tonicifying agent is
(i) sucrose or trehalose at a concentration of about 9% (w/v) or
(ii) proline at a concentration of about 3% (w/v);
(e) the concentration of chloride anion is less than about 1 mM;
and the pH of the formulation is about pH 5.0 to about pH 5.5.
13. The ophthalmic formulation of claim 12 , wherein the non-ionic surfactant is a poloxamer.
14. The ophthalmic formulation of claim 13 , wherein the non-ionic surfactant is Poloxamer 188.
15. The ophthalmic formulation of claim 12 , wherein the tonicifying agent is proline at a concentration of about 3% (w/v).
16. A method of treating an eye disorder or disease, comprising administering a therapeutically effective amount of the ophthalmic formulation of claim 1 or claim 12 by intravitreal injection to a patient in need of treatment, wherein the eye disorder or disease is selected from the group consisting of macular edema following Retinal Vein Occlusion (RVO), Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO), Neovascular (Wet) Age-Related Macular Degeneration (AMD), Impaired vision due to Myopic Choroidal Neovascularisation, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) in patients with DME, and neovascular Age-Related Macular Degeneration (AMD).
17. The method of claim 16 , wherein the eye disorder or disease is macular edema following Retinal Vein Occlusion (RVO).
18. The method of claim 16 , wherein the eye disorder or disease is Central Retinal Vein Occlusion (CRVO).
19. The method of claim 16 , wherein the eye disorder or disease is Branch Retinal Vein Occlusion (BRVO).
20. The method of claim 16 , wherein the eye disorder or disease is neovascular Age-Related Macular Degeneration (AMD) or Neovascular (Wet) Age-Related Macular Degeneration (AMD).
21. The method of claim 16 , wherein the eye disorder or disease is Impaired vision due to Myopic Choroidal Neovascularisation, Diabetic Macular Edema (DME).
22. The method of claim 16 , wherein the eye disorder or disease is Diabetic Retinopathy (DR) in patients with DME.